Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 1, 2009, Pages 107-112

  Saif, Muhammad Wasif ^a   Syrigos, K I ^b   Hotchkiss, S ^a   Shanley, J ^a   Grasso, J ^a   Ferencz, T M ^a   Syrigos, K ^a,b   Shah, M M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Cetuximab (Erbitux); Colorectal cancer; Desensitization; Epidermal growth factor receptor (EGFR); Hypersensitivity reaction; Infusion reaction; Panitumumab

Indexed keywords

ADRENALIN; BEVACIZUMAB; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; DEXAMETHASONE; DIPHENHYDRAMINE; FAMOTIDINE; FLUOROURACIL; FOLINIC ACID; HYDROCORTISONE; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PETHIDINE; PREDNISONE; SALBUTAMOL;

ADULT; AGED; ARTICLE; BACKACHE; BRONCHOSPASM; CANCER GROWTH; CASE REPORT; CHEMOEMBOLIZATION; CHEST TIGHTNESS; COLORECTAL CANCER; DESENSITIZATION; DIARRHEA; DOSE CALCULATION; DRUG ERUPTION; DRUG TOLERABILITY; DYSPNEA; FEMALE; FLUID THERAPY; FLUSHING; HUMAN; HYPOTENSION; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OXYGEN THERAPY; PATIENT MONITORING; PREMEDICATION; PRIORITY JOURNAL; SIDE EFFECT; TACHYCARDIA; THORAX PAIN; VOMITING; WHEEZING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; NEOPLASM METASTASIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 70349625831     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1009-6     Document Type: Article

References (22)

1. NE Hyne HA Lane 2005 ERBB receptors and cancer: the complexity of targeted inhibitors Nat Rev Cancer 5 341 354 10.1038/nrc1609 (Pubitemid 40637826)
2. DJ Leahy 2008 A molecular view of anti-ErbB monoclonal antibody therapy Cancer Cell 13 4 365 373 10.1016/j.ccr.2008.03.010
3. SF Wong 2005 Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer Clin Ther 27 6 684 694 16117976 10.1016/j.clinthera.2005.06.003 1:CAS:528:DC%2BD2MXnvF2rurw%3D (Pubitemid 41583517)
4. M Cohenuram MW Saif 2007 Panitumumab the first fully human monoclonal antibody: from the bench to the clinic Anticancer Drugs 18 7 15 17159497 10.1097/CAD.0b013e32800feecb 1:CAS:528:DC%2BD28Xht1yrt7bM (Pubitemid 44949790)
5. Erbitux (cetuximab) [package insert] 2005 ImClone Systems Inc/Bristol-Myers Squibb Co, New York
6. D Cunningham Y Humblet S Siena D Khayat H Bleiberg A Santoro D Bets M Mueser A Harstrick C Verslype I Chau E Van Cutsem 2004 Cetuximab monotherapy, cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 4 337 345 15269313 10.1056/NEJMoa033025 1:CAS:528: DC%2BD2cXlvFGitbk%3D (Pubitemid 38944402)
7. LB Saltz NJ Meropol PJ Loehrer Sr MN Needle J Kopit RJ Mayer 2004 Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor J Clin Oncol 22 7 1201 1208 14993230 10.1200/JCO.2004.10.182 1:CAS:528:DC%2BD2cXpsVGktLw%3D (Pubitemid 41079832)
8. JA Bonner PM Harari J Giralt N Azarnia DM Shin RB Cohen CU Jones R Sur D Raben J Jassem R Ove MS Kies J Baselga H Youssoufian N Amellal EK Rowinsky KK Ang 2006 Radiotherapy plus cetuximab for squamous-cell carcinoma of the head, neck N Engl J Med 354 6 567 578 16467544 10.1056/NEJMoa053422 1:CAS:528:DC%2BD28Xhtleksbs%3D (Pubitemid 43209104)
9. TB Gibson A Ranganathan A Grothey 2006 Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer Clin Colorectal Cancer 6 1 29 31 16796788 10.3816/CCC.2006.n.01
10. E Van Cutsem M Peeters S Siena Y Humblet A Hendlisz B Neyns JL Canon JL Van Laethem J Maurel G Richardson M Wolf RG Amado 2007 Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer J Clin Oncol 25 13 1658 1664 17470858 10.1200/JCO.2006.08.1620 (Pubitemid 46797944)
11. E Van Cutsem S Siena Y Humblet JL Canon J Maurel E Bajetta B Neyns D Kotasek A Santoro W Scheithauer S Spadafora RG Amado N Hogan M Peeters 2008 An open-label, single-arm study assessing safety, efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy Ann Oncol 19 1 92 98 17785764 10.1093/annonc/mdm399
12. Vectibix (panitumumab) [package insert] 2006 Agmen, Thousand Oaks, California
13. MW Saif J Peccerillo V Potter 2009 Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature Cancer Chemother Pharmacol 63 6 1017 1022 18781300 10.1007/s00280-008-0831-6
14. J Heun K Holen 2007 Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report Clin Colorectal Cancer 6 7 529 531 17553202 10.3816/CCC.2007.n.019
15. D Helbling M Borner 2007 Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab Ann Oncol 18 5 963 964 17488734 10.1093/annonc/mdm130 1:STN:280:DC%2BD2s3nvVOktg%3D%3D (Pubitemid 47054100)
16. DL Nielsen P Pfeiffer BV Jensen 2006 Re-treatment with cetuximab in patients with severe hypersensitivity reactions to cetuximab, two case reports Acta Oncol 45 8 1137 1138 17118853 10.1080/02841860600871764 (Pubitemid 44808504)
17. B Melichar J Cerman Jr E Malírová 2007 Successful management of infusion reaction accompanying the start of cetuximab therapy Support Care Cancer 15 4 445 449 17103198 10.1007/s00520-006-0159-x (Pubitemid 46697013)
18. SP Kang MW Saif 2007 Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer-identification, prevention, and management J Support Oncol 5 9 451 457 18019853 1:CAS:528:DC%2BD2sXhtlKhtrrP
19. MN Needle 2002 Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody Semin Oncol 29 5 Suppl 14 55 60 12422314 10.1053/sonc.2002.35648 1:CAS:528:DC%2BD38XoslWiurg%3D
20. LE van der Kolk AJ Grillo-López JW Baars CE Hack MH van Oers 2001 Complement activation plays a key role in the side-effects of rituximab treatment Br J Haematol 115 4 807 811 11843813 10.1046/j.1365-2141.2001.03166.x (Pubitemid 34042897)
21. JC Byrd JK Waselenko TJ Maneatis T Murphy FT Ward BP Monahan MA Sipe S Donegan CA White 1999 Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects, rapid blood tumor clearance J Clin Oncol 17 3 791 795 10071268 1:CAS:528:DyaK1MXhvFGgur4%3D
22. National Cancer Institute (2006) Common Terminology Criteria for Adverse Events v3.0. (CTCAE)